VectivBio Holding AG (VECT): Price and Financial Metrics
VECT Price/Volume Stats
| Current price | $16.85 | 52-week high | $16.98 |
| Prev. close | $16.85 | 52-week low | $4.25 |
| Day low | $16.80 | Volume | 130,400 |
| Day high | $16.88 | Avg. volume | 545,546 |
| 50-day MA | $14.67 | Dividend yield | N/A |
| 200-day MA | $9.71 | Market Cap | 573.24M |
VECT Stock Price Chart Interactive Chart >
VectivBio Holding AG (VECT) Company Bio
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Latest VECT News From Around the Web
Below are the latest news stories about VECTIVBIO HOLDING AG that investors may wish to consider to help them evaluate VECT as an investment opportunity.
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesBOSTON & BASEL, Switzerland, June 29, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the "Shares") for $17.00 per share in cash (the |
VectivBio Extraordinary General Meeting of Shareholders Approved All ProposalsBASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. (“Ironwood”) to acquire all of |
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBioBOSTON & BASEL, Switzerland, June 16, 2023--Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Ironwood’s pending acqui |
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio. |
Why Ironwood Pharmaceuticals Stock Bumped Higher TodayIronwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). Investors were clearly warm to that move, as they subsequently traded up Ironwood stock by almost 4% on the day. |
VECT Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 54.16% |
| 3-year | 4.79% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 76.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...